Caro J F, Amatruda J M
J Clin Invest. 1982 Apr;69(4):866-75. doi: 10.1172/jci110526.
We have recently proposed that "down regulation" of the insulin receptor may be one of the many biological responses of a cell to insulin. In an attempt to further explore this hypothesis we have studied insulin action, binding, and degradation in freshly isolated hepatocytes from rats rendered insulin resistant by the administration of dexamethasone, 1.0 mg/kg every other day, for 1 and 4 wk, and in dexamethasone-treated (0.1 muM for 24 h) primary cultures of hepatocytes from normal rats. Dexamethasone treatment for 1 and 4 wk resulted in significant hyperinsulinemia and euglycemia when compared with age- and weight-matched control animals. Freshly isolated hepatocytes from rats treated with dexamethasone for 1 wk bound less insulin than cells from control animals. This decrease in insulin binding was reflected in a decrease in the total number of cellular insulin receptors upon solubilization of the cells. Insulin action was evaluated by the ability of insulin to stimulate the uptake of alpha-aminoisobutyric acid. The basal rate of aminoisobutyrate uptake in freshly isolated hepatocytes was enhanced by 1 wk of dexamethasone treatment, and although there was an apparent shift to the right in the dose-response curve for insulin-stimulated aminoisobutyrate uptake, at no insulin concentration was there a significant difference in the uptake by hepatocytes from control and dexamethasone-treated animals. This was true whether expressed as a percentage or absolute increment above basal. Insulin degradation was enhanced in hepatocytes from animals treated with dexamethasone for 1 wk but could not account for the observed changes in insulin binding. Hepatocytes from animals treated with dexamethasone for 4 wk were resistant to insulin with regard to aminoisobutyrate uptake, yet both insulin binding and insulin degradation returned to the levels observed in hepatocytes from control animals. Primary cultures of hepatocytes from normal rats exposed to dexamethasone, 0.1 muM, in vitro for 24 h were similar to hepatocytes from rats treated with dexamethasone for 4 wk in that they were insulin resistant with regard to aminoisobutyrate uptake and had normal to increased insulin binding. Insulin degradation was also similar. These cells were resistant to the ability of insulin, 0.1 muM, to down regulate its receptor whereas parallel cultures treated with insulin in the absence of dexamethasone had a 52% decrease in insulin binding. These data indicate that hepatocytes that are insulin responsive respond to in vivo hyperinsulinemia by a decrease in the number of insulin receptors and by increased insulin degradation. Hepatocytes rendered resistant to insulin both in vivo and in vitro are resistant to these effects of insulin. These studies emphasize the importance of postbinding events in the modulation of insulin binding, action, and degradation, and support the hypothesis that down regulation of the hepatocyte insulin receptor is one of the many biological actions of insulin. They also help explain how a cell can be insulin resistant and have a normal number of insulin binding sites in the presence of hyperinsulinemia.
我们最近提出,胰岛素受体的“下调”可能是细胞对胰岛素的众多生物学反应之一。为了进一步探讨这一假说,我们研究了从每隔一天给予1.0 mg/kg地塞米松、持续1周和4周而产生胰岛素抵抗的大鼠新鲜分离的肝细胞,以及正常大鼠经地塞米松处理(0.1 μM,24小时)的原代肝细胞培养物中的胰岛素作用、结合和降解情况。与年龄和体重匹配的对照动物相比,地塞米松处理1周和4周导致显著的高胰岛素血症和血糖正常。经地塞米松处理1周的大鼠新鲜分离的肝细胞比对照动物的细胞结合的胰岛素更少。这种胰岛素结合的减少反映在细胞溶解后细胞胰岛素受体总数的减少上。通过胰岛素刺激α-氨基异丁酸摄取的能力来评估胰岛素作用。地塞米松处理1周可提高新鲜分离肝细胞中氨基异丁酸盐的基础摄取率,尽管胰岛素刺激的氨基异丁酸盐摄取的剂量反应曲线明显右移,但在任何胰岛素浓度下,对照动物和地塞米松处理动物的肝细胞摄取量均无显著差异。无论是以基础值以上的百分比还是绝对增量表示,都是如此。地塞米松处理1周的动物肝细胞中胰岛素降解增强,但这并不能解释观察到的胰岛素结合变化。经地塞米松处理4周的动物肝细胞在氨基异丁酸盐摄取方面对胰岛素耐药,但胰岛素结合和胰岛素降解均恢复到对照动物肝细胞中观察到的水平。正常大鼠的肝细胞原代培养物在体外暴露于0.1 μM地塞米松24小时,与经地塞米松处理4周的大鼠肝细胞相似,即它们在氨基异丁酸盐摄取方面对胰岛素耐药,胰岛素结合正常或增加。胰岛素降解也相似。这些细胞对0.1 μM胰岛素下调其受体的能力耐药,而在无地塞米松的情况下用胰岛素处理的平行培养物中胰岛素结合减少了52%。这些数据表明,对胰岛素有反应的肝细胞通过减少胰岛素受体数量和增加胰岛素降解来应对体内高胰岛素血症。在体内和体外对胰岛素耐药的肝细胞对胰岛素的这些作用耐药。这些研究强调了结合后事件在调节胰岛素结合、作用和降解中的重要性,并支持肝细胞胰岛素受体下调是胰岛素众多生物学作用之一的假说。它们还有助于解释在高胰岛素血症存在的情况下,细胞如何对胰岛素耐药但仍具有正常数量的胰岛素结合位点。